• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/8/21 10:17:35 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email
    SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 BIO-RAD LABORATORIES INC CLASS A COMMON STOCK Cusip #090572207 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #090572207 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 270,714 Item 6: 0 Item 7: 1,692,254 Item 8: 0 Item 9: 1,692,254 Item 11: 6.840% Item 12: HC Cusip #090572207 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,692,254 Item 8: 0 Item 9: 1,692,254 Item 11: 6.840% Item 12: IN Item 1(a). Name of Issuer: BIO-RAD LABORATORIES INC Item 1(b). Address of Issuer's Principal Executive Offices: 1000 Alfred Nobel Drive Hercules, CA 94547 Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 090572207 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 1,692,254 (b) Percent of Class: 6.840% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 270,714 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,692,254 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC. No one other person's interest in the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA FMR Investment Management (UK) Limited FI Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of BIO-RAD LABORATORIES INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $BIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIO

    DatePrice TargetRatingAnalyst
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    8/28/2024$340.00Equal Weight
    Wells Fargo
    6/3/2024$315.00Hold
    Jefferies
    4/3/2024$400.00 → $365.00Buy → Neutral
    Citigroup
    12/7/2023$395.00Buy
    UBS
    6/16/2023$550.00Overweight
    Wells Fargo
    12/7/2022$565.00Outperform
    RBC Capital Mkts
    8/25/2022$715.00Outperform
    Credit Suisse
    More analyst ratings

    $BIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bio-Rad Labs upgraded by Citigroup with a new price target

      Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously

      10/1/24 7:11:23 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Bio-Rad Labs with a new price target

      Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00

      8/28/24 7:34:48 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Bio-Rad Labs with a new price target

      Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00

      6/3/24 8:40:37 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider May Simon claimed ownership of 43 units of Bio-Rad A Common Stock

      3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      1/7/22 1:09:06 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4: Wright Dara converted options into 502 units of Bio-Rad A Common Stock and covered exercise/tax liability with 221 units of Bio-Rad A Common Stock, increasing direct ownership by 46% to 892 units

      4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      12/17/21 2:21:01 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4: Schwartz Norman D received a gift of 40 units of Bio-Rad B Common Stock, increasing direct ownership by 0.01% to 316,146 units

      4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      11/23/21 2:30:23 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in reve

      5/29/25 4:30:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life

      5/12/25 4:30:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Reports First-Quarter 2025 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

      5/1/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    SEC Filings

    See more
    • Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      11/18/21 4:46:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Bio-Rad Laboratories, Inc.

      10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      10/29/21 4:06:54 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      10/28/21 4:27:41 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D

      8/20/24 8:30:00 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo

      3/20/24 8:30:00 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Financials

    Live finance-specific insights

    See more
    • Bio-Rad Reports First-Quarter 2025 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

      5/1/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available

      4/15/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: "Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins." Mr. Schwartz continued: "We begin 2025 in a strong position and remain committed to advancing

      2/13/25 4:20:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

      2/10/21 10:39:36 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed

      SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

      2/8/21 10:17:35 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials